{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:15Z","timestamp":1787028495219,"version":"build-2736575974"},"reference-count":40,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"French Institute for Health and Medical Research (INSERM)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Acute heart failure (AHF) due to acute myocardial infarction (AMI) is likely to involve cardiogenic shock (CS), with neuro-hormonal activation. A relationship between AHF, CS and vasopressin response is suspected. This study aimed to investigate the implication of vasopressin on hemodynamic parameters and tissue perfusion at the early phase of CS complicating AMI. Experiments were performed on male Wistar rats submitted or not to left coronary artery ligation (AMI and Sham). Six groups were studied Sham and AMI treated or not with either a vasopressin antagonist SR-49059 (Sham-SR, AMI-SR) or agonist terlipressin (Sham-TLP, AMI-TLP). Animals were sacrificed one day after surgery (D1) and after hemodynamic parameters determination. Vascular responses to vasopressin were evaluated, ex vivo, on aorta. AHF was defined by a left ventricular ejection fraction below 40%. CS was defined by AHF plus tissue hypoperfusion evidenced by elevated serum lactate level or low mesenteric oxygen saturation (SmO2) at D1. Mortality rates were 40% in AMI, 0% in AMI-SR and 33% in AMI-TLP. Immediately after surgery, a sharp decrease in SmO2 was observed in all groups. At D1, SmO2 recovered in Sham and in SR-treated animals while it remained low in AMI and further decreased in TLP-treated groups. The incidence of CS among AHF animals was 72% in AMI or AMI-TLP while it was reduced to 25% in AMI-SR. Plasma copeptin level was increased by AMI. Maximal contractile response to vasopressin was decreased in AMI (32%) as in TLP- and SR- treated groups regardless of ligation. Increased vasopressin secretion occurring in the early phase of AMI may be responsible of mesenteric hypoperfusion resulting in tissue hypoxia. Treatment with a vasopressin antagonist enhanced mesenteric perfusion and improve survival. This could be an interesting therapeutic strategy to prevent progression to cardiogenic shock.<\/jats:p>","DOI":"10.3390\/ijms24021325","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T01:57:48Z","timestamp":1673315868000},"page":"1325","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Involvement of Vasopressin in Tissue Hypoperfusion during Cardiogenic Shock Complicating Acute Myocardial Infarction in Rats"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1192-8704","authenticated-orcid":false,"given":"Philippe","family":"Gaudard","sequence":"first","affiliation":[{"name":"PhyMedExp, Universit\u00e9 Montpellier, INSERM, CNRS, 34295 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"David","sequence":"additional","affiliation":[{"name":"CHU de Montpellier, 34090 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-148X","authenticated-orcid":false,"given":"Patrice","family":"Bideaux","sequence":"additional","affiliation":[{"name":"PhyMedExp, Universit\u00e9 Montpellier, INSERM, CNRS, 34295 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sicard","sequence":"additional","affiliation":[{"name":"PhyMedExp, Universit\u00e9 Montpellier, INSERM, CNRS, 34295 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8563-7278","authenticated-orcid":false,"given":"Jean-Paul","family":"Cristol","sequence":"additional","affiliation":[{"name":"CHU de Montpellier, 34090 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Guillon","sequence":"additional","affiliation":[{"name":"Institut de G\u00e9nomique Fonctionnelle, Universit\u00e9 Montpellier, INSERM, CNRS, 34094 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9460-6705","authenticated-orcid":false,"given":"Sylvain","family":"Richard","sequence":"additional","affiliation":[{"name":"PhyMedExp, Universit\u00e9 Montpellier, INSERM, CNRS, 34295 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Colson","sequence":"additional","affiliation":[{"name":"CHU de Montpellier, 34090 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5819-3306","authenticated-orcid":false,"given":"Anne","family":"Virsolvy","sequence":"additional","affiliation":[{"name":"PhyMedExp, Universit\u00e9 Montpellier, INSERM, CNRS, 34295 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/CIRCULATIONAHA.106.613596","article-title":"Cardiogenic Shock: Current Concepts and Improving Outcomes","volume":"117","author":"Reynolds","year":"2008","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.acvd.2019.02.001","article-title":"Design and Preliminary Results of FRENSHOCK 2016: A Prospective Nationwide Multicentre Registry on Cardiogenic Shock","volume":"112","author":"Delmas","year":"2019","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00134-018-5214-9","article-title":"Management of Cardiogenic Shock Complicating Myocardial Infarction","volume":"44","author":"Mebazaa","year":"2018","journal-title":"Intensive Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e011991","DOI":"10.1161\/JAHA.119.011991","article-title":"Cardiogenic Shock","volume":"8","author":"Vahdatpour","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0735-1097(00)00879-2","article-title":"Cardiogenic Shock Complicating Acute Myocardial Infarction\u2014Etiologies, Management and Outcome: A Report from the SHOCK Trial Registry. SHould We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock?","volume":"36","author":"Hochman","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.amjcard.2005.07.076","article-title":"Effect of Vasopressin on Hemodynamics in Patients with Refractory Cardiogenic Shock Complicating Acute Myocardial Infarction","volume":"96","author":"Jolly","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"R255","DOI":"10.1186\/cc10516","article-title":"Post Cardiac Surgery Vasoplegia Is Associated with High Preoperative Copeptin Plasma Concentration","volume":"15","author":"Colson","year":"2011","journal-title":"Crit. Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1161\/CIRCULATIONAHA.106.685503","article-title":"C-Terminal Provasopressin (Copeptin) as a Novel and Prognostic Marker in Acute Myocardial Infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study","volume":"115","author":"Khan","year":"2007","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijcard.2018.09.022","article-title":"Copeptin as a Prognostic Biomarker in Acute Myocardial Infarction","volume":"274","author":"Lattuca","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"901990","DOI":"10.3389\/fcvm.2022.901990","article-title":"Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases","volume":"9","author":"Mu","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","article-title":"Increased Plasma Arginine Vasopressin Levels in Patients with Congestive Heart Failure","volume":"1","author":"Goldsmith","year":"1983","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2018.04.051","article-title":"Epinephrine versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction","volume":"72","author":"Levy","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.44.4.503","article-title":"Myocardial Infarct Size and Ventricular Function in Rats","volume":"44","author":"Pfeffer","year":"1979","journal-title":"Circ. Res."},{"key":"ref_15","first-page":"57","article-title":"Experimental Myocardial Infarction in the Rat: Qualitative and Quantitative Changes during Pathologic Evolution","volume":"90","author":"Fishbein","year":"1978","journal-title":"Am. J. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.carrev.2005.07.001","article-title":"A Novel Method for Safe and Accurate Left Anterior Descending Coronary Artery Ligation for Research in Rats","volume":"6","author":"Samsamshariat","year":"2005","journal-title":"Cardiovasc. Revasc. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-4939-8597-5_13","article-title":"Ischemic Model of Heart Failure in Rats and Mice","volume":"1816","author":"Chen","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kainuma, S., Miyagawa, S., Fukushima, S., Tsuchimochi, H., Sonobe, T., Fujii, Y., Pearson, J.T., Saito, A., Harada, A., and Toda, K. (2017). Influence of Coronary Architecture on the Variability in Myocardial Infarction Induced by Coronary Ligation in Rats. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183323"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1172\/JCI116554","article-title":"Biochemical and Pharmacological Properties of SR 49059, a New, Potent, Nonpeptide Antagonist of Rat and Human Vasopressin V1a Receptors","volume":"92","author":"Wagnon","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of Neuroendocrine Activation in Patients with Left Ventricular Dysfunction with and without Congestive Heart Failure. A Substudy of the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0735-1097(94)90001-9","article-title":"Prognostic Value of Neurohumoral Activation in Patients with an Acute Myocardial Infarction: Effect of Captopril","volume":"24","author":"Rouleau","year":"1994","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","article-title":"Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of Vasopressin","volume":"52","author":"Morgenthaler","year":"2006","journal-title":"Clin. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1177\/0148607113496117","article-title":"The Surgically Induced Stress Response","volume":"37","author":"Finnerty","year":"2013","journal-title":"JPEN J. Parenter. Enter. Nutr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0002-9343(88)90206-9","article-title":"Neuroendocrine Changes in Acute Myocardial Infarction","volume":"84","author":"McAlpine","year":"1988","journal-title":"Am. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/hrt.60.2.117","article-title":"Neuroendocrine Activation after Acute Myocardial Infarction","volume":"60","author":"McAlpine","year":"1988","journal-title":"Br. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"28I","DOI":"10.1016\/0002-9149(90)90122-H","article-title":"Neuroendocrine Activation after Acute Myocardial Infarction","volume":"65","author":"Cohn","year":"1990","journal-title":"Am. J. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1136\/hrt.72.2_Suppl.S28","article-title":"Neuroendocrine Excitation in Heart Failure","volume":"72","author":"Riegger","year":"1994","journal-title":"Br. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal Activation in Heart Failure with Reduced Ejection Fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/cc2337","article-title":"Science Review: Vasopressin and the Cardiovascular System Part 1\u2014Receptor Physiology","volume":"7","author":"Holmes","year":"2003","journal-title":"Crit. Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.phrs.2016.08.027","article-title":"Terlipressin, a Vasoactive Prodrug Recommended in Hepatorenal Syndrome, Is an Agonist of Human V1, V2 and V1B Receptors: Implications for Its Safety Profile","volume":"113","author":"Colson","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jphs.13R13CP","article-title":"Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure","volume":"124","author":"Izumi","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4330\/wjc.v6.i12.1252","article-title":"Arginine Vasopressin as a Target in the Treatment of Acute Heart Failure","volume":"6","author":"Gilotra","year":"2014","journal-title":"World J. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bpa.2008.02.006","article-title":"Terlipressin in the Treatment of Septic Shock: The Earlier the Better?","volume":"22","author":"Morelli","year":"2008","journal-title":"Best Pract. Res. Clin. Anaesthesiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/01.CCM.0000206466.56669.BE","article-title":"Decreased Vasopressin Responsiveness in Vasodilatory Septic Shock-like Conditions","volume":"34","author":"Leone","year":"2006","journal-title":"Crit. Care Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1440-1681.1996.tb02589.x","article-title":"CNS Pathways Mediating Cardiovascular Regulation of Vasopressin","volume":"23","author":"Renaud","year":"1996","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s13054-019-2643-y","article-title":"Exogenous Vasopressin Dose-Dependently Modulates Gastric Microcirculatory Oxygenation in Dogs via V1A Receptor","volume":"23","author":"Truse","year":"2019","journal-title":"Crit. Care"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40635-018-0201-6","article-title":"ESICM LIVES 2018: Paris, France. 20\u201324 October 2018","volume":"6","author":"Gaudard","year":"2018","journal-title":"Intensive Care Med. Exp."},{"key":"ref_38","unstructured":"(2023, January 04). Histological Quantification of Chronic Myocardial Infarct in Rats\u2014Video. Available online: https:\/\/www.jove.com\/t\/54914\/histological-quantification-of-chronic-myocardial-infarct-in-rats."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbadis.2018.08.005","article-title":"Early Calcium Handling Imbalance in Pressure Overload-Induced Heart Failure with Nearly Normal Left Ventricular Ejection Fraction","volume":"1865","author":"Rouhana","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Fort, A., Cordaillat, M., Thollon, C., Salazar, G., Mechaly, I., Villeneuve, N., Vilaine, J.-P., Richard, S., and Virsolvy, A. (2009). New Insights in the Contribution of Voltage-Gated Na(v) Channels to Rat Aorta Contraction. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007360"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1325\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:17Z","timestamp":1760119517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24021325"],"URL":"https:\/\/doi.org\/10.3390\/ijms24021325","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]}}}